Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Jonelle K. Lee"'
Autor:
Maria R. Baer, Goutham Narla, Danilo Perrotti, Yin Wang, Jaya Sangodkar, Sandrine Niyongere, Rena G. Lapidus, Shivani Kapoor, Jonelle K. Lee, Christopher M. Bailey, Prerna Singh, Mario Scarpa
Supplementary Table S1. AML patients. Supplementary Table S2. RT-qPCR primers. Supplementary Table S3. IC50 concentrations (nM) of FLT3 inhibitors, PP2A activators and GSK-3beta inhibitors. Supplementary Figure S1. Concurrent PP2A-activating drug tre
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::86eb9d3fab43e2d25f4450c2f3c42655
https://doi.org/10.1158/1535-7163.22522443
https://doi.org/10.1158/1535-7163.22522443
Autor:
Maria R. Baer, Goutham Narla, Danilo Perrotti, Yin Wang, Jaya Sangodkar, Sandrine Niyongere, Rena G. Lapidus, Shivani Kapoor, Jonelle K. Lee, Christopher M. Bailey, Prerna Singh, Mario Scarpa
Fms-like tyrosine-like kinase 3 internal tandem duplication (FLT3-ITD) is present in acute myeloid leukemia (AML) in 30% of patients and is associated with short disease-free survival. FLT3 inhibitor efficacy is limited and transient but may be enhan
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2921d1b6556415df736f52ed8b400ce1
https://doi.org/10.1158/1535-7163.c.6543381.v1
https://doi.org/10.1158/1535-7163.c.6543381.v1
Autor:
Shivani Kapoor, Feyruz V. Rassool, Aditi Chatterjee, Ying S. Zou, Julie C. Dunning Hotopp, Jonelle K. Lee, Mario Scarpa, Prerna Singh, Maria R. Baer, Eric S. Tvedte, Moaath Mustafa Ali, Kshama A. Doshi, Robin E. Bromley
Publikováno v:
Oncotarget
Acute myeloid leukemia (AML) with fms-like tyrosine kinase 3 internal tandem duplication (FLT3-ITD) relapses with new chromosome abnormalities following chemotherapy, implicating genomic instability. Error-prone alternative non-homologous end-joining
Publikováno v:
Cancer Research. 83:5013-5013
Internal tandem duplication (ITD) of the fms-like tyrosine kinase 3 (FLT3) receptor tyrosine kinase is present in AML cells in 25% of patients, causing constitutive activation and aberrant signaling. FLT3-ITD+ AML patients have a high relapse rate fo
Autor:
Rena G. Lapidus, Jaya Sangodkar, Christopher Bailey, Danilo Perrotti, Maria R. Baer, Shivani Kapoor, Mario Scarpa, Yin Wang, Prerna Singh, Goutham Narla, Sandrine Niyongere, Jonelle K. Lee
Publikováno v:
Mol Cancer Ther
Fms-like tyrosine-like kinase 3 internal tandem duplication (FLT3-ITD) is present in acute myeloid leukemia (AML) in 30% of patients and is associated with short disease-free survival. FLT3 inhibitor efficacy is limited and transient but may be enhan
Autor:
Shivani Kapoor, Maria R. Baer, Jonelle K. Lee, Moaath Mustafa Ali, Rossana Trotta, Mario Scarpa, Aditi Chatterjee, Prerna Singh
Publikováno v:
Blood. 138:1163-1163
BACKGROUND Internal tandem duplication in the fms-like tyrosine kinase 3 receptor tyrosine kinase (FLT3-ITD) is present in acute myeloid leukemia (AML) in 30% of patients, associated with poor treatment outcomes due to rapid relapse. FLT3 inhibitors
Autor:
Sandrine Niyongere, Shivani Kapoor, Jonelle K. Lee, Danilo Perrotti, Mario Scarpa, Prerna Singh, Maria R. Baer, Goutham Narla
Publikováno v:
Blood. 134:1276-1276
Introduction fms-like tyrosine like kinase 3 internal tandem duplication (FLT3-ITD), present in acute myeloid leukemia (AML) cells of 30% of patients, results in constitutive and aberrant FLT3 signaling and, clinically, short disease-free survival. E